Pharma Archives - Blogs & Articles

Biomarkers & Their Increasingly Crucial Role in Drug Development

August 9, 2022November 14, 2022 MarketsandMarkets Conferences

The Coronavirus massively highlighted a few distinct factors of the healthcare system. Primarily was the need for rapid drug development (in the form of various vaccines for Covid-19) and more importantly how important the identification of diseases at the earliest stages could not only reduce the chances of mortality for an individual but also allow for better quarantine measures to avoid epidemics which possess the potential to expand into future pandemics. With each passing year, technology has allowed us to delve deeper into the human anatomy & grow our existing…

Speaker Spotlight – ‘Rachel Legmann ’ : 4th Annual MarketsandMarkets Next-Gen Bioprocessing Conference!

July 29, 2022July 29, 2022 MarketsandMarkets Conferences

The 4th Annual MarketsandMarkets Next-Gen Bioprocessing Conference on the 20th & 21st of October 2022 aims to delve deep into defining trends & innovation withing the bioprocessing ecosystem around major domains like cell culture & bioproduction, downstream processing & continuous biomanufacturing and cell and gene therapy analytics. Just under 12 weeks remain till we go LIVE in Boston with over 100+ attendees, in-depth case studies, various networking sessions & keynote presentations from 15+ leading industry experts. We’re tremendously excited to hear the speakers’ ideas, findings & foresight into the future….

Speaker Spotlight – ‘Joseph M. Roig’ : 4th Annual MarketsandMarkets Next-Gen Bioprocessing Conference!

July 25, 2022July 29, 2022 MarketsandMarkets Conferences

Boston plays host to the 4th Annual MarketsandMarkets Next-Gen Bioprocessing Conference on the 20th & 21st of October 2022 and we’re literally counting down the days! With over 100+ attendees & in-depth case studies & keynote presentations from 15+ leading industry experts, the event promises to deliver a comprehensively enriching experience! As we keenly await to discover the speakers’ ideas, findings & foresight into the future of topics surrounding cell culture & bioproduction, downstream processing & continuous biomanufacturing and cell and gene therapy analytics, here’s a glimpse into what you…

Expanding the Horizons of Healthcare Monitoring – Real World Data & Evidence!

July 19, 2022July 25, 2022 MarketsandMarkets Conferences

The lifecycle of drug development, right from moment of conception till the time its approved for widespread usage, is an extremely long & complex one. The amount of data generated through trials or acquired from various points of collection, which is required to be analysed during this process is humongous. For a drug to be effective, the patient data which forms the foundation of its development, must closely reflect the conditions of the demographic or section of people it is intended for. This is where, Real World Data (RWD)…

Precision Medicine – A Deep Dive into Personalized Therapy & Treatment

June 22, 2022June 22, 2022 MarketsandMarkets Conferences

For the healthcare ecosystem across the world, the underlying purpose has always been to fight & eradicate illnesses in the shortest amount of time hence corelating with minimal pain, suffering or stress for the patients involved. Rapid technological advancements in the 21st century have meant that a humongous amount of clinical data and testing methods required to analyse it, exist during the same period. This has subsequently allowed for the emergence of ‘Precision Medicine’. Also referred to as Personalized Medicine, it is an innovative approach towards medicinal care.By utilizing the…

Companion Diagnostics & Biomarkers – Paving the way for Personalized Medicine

May 25, 2022 MarketsandMarkets Conferences

Prior to and only enhanced by the pandemic, in vitro analysis of biological specimens like tissue samples or blood amongst others plays a huge role in guiding accurate diagnosis & subsequent therapy. When used in tandem with a specific therapeutic drug or medicine and relying on the presence or absence of a predictive biomarker, such IVD are known as Companion Diagnostics (CDx). A companion diagnostic is essentially a medical device while helps differentiate patients between responders & non responders with reference to a certain drug or therapy. For example, a…

Developments & Challenges within the Single Cell Analysis Ecosystem

May 17, 2022August 16, 2023 MarketsandMarkets Conferences

With just over a month till the MarketsandMarkets BioPharma Series kicks off in Boston on the 23rd & 24th of June 2022, we believed it would be apt to unveil a glimpse of the enriching insights our esteemed speakers shall be bringing to the tri-conference event. On the eve of our 3rd Annual MarketsandMarkets Single-Cell Analysis Conference, we sat down with Jun Wang, Associate Professor (Department of Biomedical Engineering) at Stony Brook University, New York who is also a keynote speaker at the conference. As part of the conversation, we…

Immuno-Oncology : The Latest Frontier in Cancer Therapy

April 28, 2022August 16, 2023 MarketsandMarkets Conferences

For as long as medicine has existed, cancers have ravaged humanity. The search for an eventual cure has been a tremendous & tireless pursuit, selflessly undertaken by doctors, researchers, scientists & the entire healthcare community. With each passing year and the availability of sophisticated technologies, their efforts continue to go from strength to strength, expanding our means to adequately cope, manage and possibly rebuff the disease which has so often reminded us of our mortality. Up until recently, Chemotherapy, Surgeries, Radiation & Targeted Drug therapies had been the go-to for…

BIOSIMILARS: Origins & The Path Forward

April 19, 2022August 16, 2023 MarketsandMarkets Conferences

Almost 7 years removed from the first FDA approved Biosimilar (Zarxio) in 2015, the US market for Biosimilars is projected to be highly beneficial over the next decade, for both pharmaceutical companies as well as patients, with RAND Corporation projecting estimated savings of over $54 Billion during this period. To truly comprehend such forecasts, a deeper understanding of what constitutes a ‘Biosimilar Drug’ is required. Essentially, the structure of a biosimilar is based on a pre-existing, approved drug known as a Biologic & possesses no significant clinical difference in safety,…

Catch up with Matt Davis’ talk on “Neoantigen Targeted Cancer Immunotherapy in the Clinic” at Advance Genetic Sequencing Virtual Conference 2021

September 14, 2021September 20, 2021 MarketsandMarkets Conferences

Matt Davis PhD joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is currently the Director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and translational genomics efforts. Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group. He holds a PhD in Genetics from Yale with thesis research under the supervision of Dr. Joseph Schlessinger and previous to his graduate work he conducted cancer genomics research at Dana Farber Cancer Institute and the Broad Institute. Marketsandmarkets took this opportunity to talk…